Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.21% is 27% above its 3-year average of 0.17%, near the low end of its 3-year range (0.00%–23.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 97.66% below its 12-month average of 9.02%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.21%.
DEBT TO ASSETS RATIO
0.21%
DEBT TO ASSETS RATIO AVG TTM
9.02%
DEBT TO ASSETS RATIO AVG 3Y
0.17%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-97.66%
CURRENT VS 3Y AVG
+27.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+134.49%
vs the sector median at left
Palvella Therapeutics, Inc.
Market Cap
$1.84B
Debt to Assets Ratio
0.21%
TTM Avg
9.02%
3Y Avg
0.17%
5Y Avg
N/A
Market Cap
$1.83B
Debt to Assets Ratio
0.43%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.83B
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.81B
Debt to Assets Ratio
0.30%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.87B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.84B | 0.21% | 9.02% | 0.17% | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 0.43% | N/A | N/A | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | 0.33% | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.85B | 0.01% | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.81B | 0.03% | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.86B | 0.31% | N/A | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 0.30% | N/A | N/A | N/A |
| Xencor, Inc. (XNCR)vs › | $1.81B | 0.09% | N/A | N/A | N/A |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | 0.00% | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 0.04% | N/A | N/A | N/A |
Debt/Assets
0.2%
Debt/Equity
0.00
Current Ratio
21.18
Interest Coverage
-6.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.21% |
| 2026-03-31 | 0.22% |
| 2025-12-31 | 1.06% |
| 2025-09-30 | 23.93% |
| 2025-06-30 | 19.68% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 20.70% |
